Omeros Slides 18% as Q3 Revenue Misses Despite Adjusted Beat
OMER has more than doubled off its 52-week low of $6.702 on elevated volume (2.5× avg).
Summary
Omeros is down 17.81% at $13.71 Tuesday on 2.57 million shares, roughly 65.5% above its 100-day average volume, after Q3 revenue of $35.93 million came in below the $37.27 million consensus. Adjusted EPS of 6 cents beat the 3 cents estimate, and the reported $57.4 million net loss was driven by a $62 million non-cash derivative remeasurement tied to the 2029 convertible notes, not operations. The underlying business is improving: Yartemlea net revenue rose 26% sequentially to $35.9 million, operating income was $4.5 million versus a $26.4 million loss a year earlier, and the quarter produced $13.3 million of positive operating cash flow with $95.3 million in cash and short-term investments at quarter end. The company also retired $30.5 million of 2029 convertible notes for $60.2 million, cutting outstanding principal to about $40.3 million. Novo Nordisk remains on track to start a Phase 3 trial of zaltenibart, with Omeros eligible for more than $1.8 billion in milestones including up to $100 million near term; the October CHMP negative opinion on narsoplimab still blocks EU approval.
At the time of this announcement, OMER was trading at $13.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $6.70 to $21.24. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.